HARROW HEALTH HROW 深 沪
已收盘 09-26 16:00:00 美东时间
47.10
+0.950
+2.06%
华盛通- 最 高50.72
- 今 开46.29
- 成交量 132.66万股
- 最 低 46.29
- 昨 收 46.15
- 总市值 17.43亿
- 52周最高 59.23
- 市盈率 静 --
- 换手率 3.59%
- 52周最低 20.85
- 委 比 34.34%
- 总股本 3700.21万
- 历史最高 59.23
- 量 比 1.88
- 振 幅 9.60%
- 历史最低 3.33
- 每 手 1
- 风险率 13.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Harrow Health Acquires Melt Pharmaceuticals for Expansion
Harrow Health ( ($HROW) ) has issued an update. On September 26, 2025, Harrow a...
09-26 19:28
Harrow to buy Melt Pharmaceuticals
Harrow (NASDAQ:HROW) to acquire Melt Pharmaceuticals, a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, a...
09-26 19:10
Harrow To Acquire Melt Pharma, Advancing Sublingual Sedation Therapy MELT-300 Toward 2027 NDA After Positive Phase 3 Results
Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into an agreement to acquire Melt Pharmaceuticals, Inc., a
09-26 19:03
Harrow Launches Harrow Access for All (HAFA)
Harrow launched its HAFA program to expand access to its ophthalmic medications, building on the successful VAFA initiative. HAFA offers affordable pricing, with out-of-pocket costs capped at $59, and streamlines the prescribing process through the HarrowAccess.com portal. The program will be implemented in three phases, starting late 2025, covering all products by 2027.
09-25 20:05
美股大行评级 | 升至450美元，瑞穗上调特斯拉目标价；富国银行上调CoreWeave至"超配"，目标价升至170美元
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从44美元升至84美元；Oppenheimer：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至80美元
09-24 10:23
Demystifying Harrow: Insights From 5 Analyst Reviews
In the latest quarter, 5 analysts provided ratings for Harrow (NASDAQ:HROW), sh...
09-24 04:01
Craig-Hallum Maintains Buy on Harrow, Raises Price Target to $64
Craig-Hallum analyst Chase Knickerbocker maintains Harrow (NASDAQ:HROW) with a Buy and raises the price target from $54 to $64.
09-23 21:51
Harrow Announces Agenda and Speakers for Investor & Analyst Day
Harrow, a leading provider of ophthalmic disease management solutions, will host its Investor & Analyst Day on September 26, 2025, in New York. The event, webcast live, will feature presentations from Harrow’s leadership team, renowned physicians, and key opinion leaders on the company’s business, pipeline, and long-term vision. Topics include financial updates, product overviews, and expert perspectives on treatments like dry eye disease, retina...
09-15 11:00
Harrow launches $250M debt offering
Harrow (NASDAQ:HROW) has commenced a private offering of $250.0 million aggregate principal amount of senior unsecured notes due 2030. The company plans to use proceeds from the offering to fully repa...
09-08 20:26
Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030
Harrow announced a private offering of $250 million in senior unsecured notes due 2030 and a new $40 million revolving credit facility. The company will use proceeds to repay its Oaktree facility, redeem $75 million 8.625% Notes and $40.25 million 11.875% Notes, and for general corporate purposes. Conditional notices of redemption for the 2027 and 2026 Notes were issued, with redemption subject to offering completion.
09-08 12:00
